1. Scrip
  2. >>Business

Kezar Puts All Its Eggs In One Basket

 
• By Elizabeth Cairns

The group is instituting swingeing cuts to allow it to get to a mid-stage readout for zetomipzomib in lupus nephritis. What if the trial fails?   

Eggs_Basket

A great deal is riding on the outcome of the Phase IIb study of Kezar Life Sciences, Inc.’s zetomipzomib (KZR-616) in lupus nephritis, and the company is throwing the few resources it has at completing the study. It is canning 41% of its workforce and has halted all drug discovery activities in an attempt to extend its cash runway to the study’s expected reporting date of 2026.

Key Takeaways
  • Kezar is cutting staff and R&D in order to fund the mid-stage trial of its lupus nephritis candidate
  • The company is now hugely reliant on the readout, due in 2026
  • And earlier trial data were less than

The company badly needs the PALIZADE study to hit if it is to keep the lights on beyond that point

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Industry Makes Its Case To Trump In Effort To Sidestep Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a 232 investigation.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

Stock Watch: Market Optimism Outshines Q1 Currency And Tariff Woes

 
• By Andy Smith

The weak US dollar helped some companies reporting first-quarter results and hindered others reporting in stronger currencies. But even the impacts of currencies and Medicare modernization on first-quarter revenues were overlooked when an end to the trade wars seemed possible.